FT3, free triiodothyronine
By combining GLP-1, GIP and glucagon receptor activity into a single weekly injection, it has the potential to deliver greater weight loss than current therapies while also improving blood sugar control, metabolic health and markers of cardiovascular and liver disease
This initiative allows individuals to earn commissions for referring new customers
Important: Follow the prescription label and provider instructions for administration
is contracted via the University of Liverpool (no personal payment) to undertake consultancy for Altimmune, AstraZeneca, Boehringer Ingelheim, Cytoki, Eli Lilly, Napp, Novo Nordisk, Menarini, Pfizer, Rhythm Pharmaceuticals, Sanofi, Saniona, Tern Pharmaceuticals, Shionogi and Ysopia